Michelson Diagnostics (MDL) has announced new high speed imaging capability for its EX1301 OCT Microscope. OCT (Optical Coherence Tomography) images can be captured at up to 40 frames per second, enabling imaging of dynamic processes such as the heartbeat of a fruit-fly.
ART Advanced Research Technologies Inc. unveiled a new generation of its optical molecular imaging system, called Optix MX3.
Agios Pharmaceuticals' scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.
Bevacizumab given in addition to the combined chemotherapy regimen of gemcitabine and oxaliplatin (GEMOX-B) is well tolerated and shows promising antitumour activity in patients with advanced biliary-tract cancers.
Pharmasset Inc. will continue enrolling patients in a clinical trial of RG7128, a drug that is designed to treat the liver disease hepatitis C.
Researchers have shown how an experimental drug might restore the function of nerves damaged in spinal cord injuries by preventing short circuits caused when tiny "potassium channels" in the fibers are exposed.
Federal health experts brushed off lingering safety questions about a popular inhaler drug and suggested it carry bolder benefit claims.
Drug developer Merck & Co. said a European advisory committee recommended approval for the company's fertility drug Elonva.
Raptor Pharmaceutical Corp. said its developing treatment for the genetic disorder nephropathic cystinosis met key goals in a midstage study.
Immunovaccine Inc. said that Pfizer Inc., the world's largest drugmaker, is licensing its technology for use in vaccines for cattle.
Drugmaker Bristol-Myers Squibb Co. and Asterand PLC are extending a research collaboration for up to three years, Asterand said.
British drugmaker GlaxoSmithKline PLC says it's withdrawing its application for U.S. approval of a drug to prevent prostate cancer.
Four North Carolina patients at a single hospital tested positive for a type of swine flu that is resistant to Tamiflu, health officials said.
Genentech Inc. and partner Biogen Idec Inc. said the Food and Drug Administration is withholding a decision to expand approval of Rituxan as a leukemia treatment, pending further discussion.